GLOFIL-125
LOE Approachingsodium iothalamate i-125 injection
NDAINJECTIONINJECTABLE
Approved
Feb 1974
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
GLOFIL-125 (sodium iothalamate i-125 injection) is clinical pharmacology the renal clearance of sodium iothalamate in man closely approximates that of inulin. First approved in 1974.
Drug data last refreshed 18h ago · AI intelligence enriched 21h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
GLOFIL-125 is a radioactive diagnostic agent (sodium iothalamate I-125 injection) used to measure glomerular filtration rate (GFR) in renal function assessment. The compound is cleared exclusively by glomerular filtration without tubular involvement, making it a gold-standard measure of kidney function. It is administered by injection and has a very short effective half-life of approximately 0.07 days.
LOE Approaching
Product approaching loss of exclusivity with low linked job activity (0 roles), signaling minimal commercial team expansion and likely defensive positioning.
Mechanism of Action
CLINICAL PHARMACOLOGY The renal clearance of sodium iothalamate in man closely approximates that of inulin. The compound is cleared by glomerular filtration without tubular secretion or reabsorption. Following infusion administration of I-125 iothalamate, the effective half-life is about 0.07 days.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
GLOFIL-125 presents limited career expansion opportunities due to its approaching loss of exclusivity, minimal commercial support (0 linked roles), and mature, stable market position. Professionals joining this product team should expect defensive commercial strategy, focus on operational efficiency, and potential transition planning rather than growth-oriented development.
Product Manager
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.